Meanwhile, the Russian health ministry, which has not yet confirmed the August approval date, said that the frontline medical staff will be first to be vaccinated once the new drug has been approved for public use, whereas, the country's defence ministry said that Russian soldiers served as volunteers in human trials. So, apprehensions remain over the safety and efficacy of the vaccine.
The trial's primary endpoints will be prevention of COVID-19 in those who have not been infected by SARS-CoV-2 as well as the prevention of COVID-19 regardless of whether they have previously had the virus.
Half of participants will receive the vaccine, and half will receive a saltwater placebo.
Pfizer said its potential vaccine emerged as a strong candidate based on assessments of its safety and immune response.
Dr. Anthony Fauci, the country's top infectious disease official, said rising rates of virus transmission in other parts of the US, while unfortunate, could speed vaccine development by offering researchers a better view into how well the drug blocks the progression of COVID-19.
Another vaccine being developed by the Vektor State laboratory near the Siberian city of Novosibirsk should be launched in October, she added. Pfizer has a pact to sell the winning vaccine for 50 million people to the USA government for around $2 billion, should it pass through the clinical hurdles. Notably, monkeys receiving both dose levels produced these antibodies at levels higher than those found in humans who have recovered from Covid-19. Blood tests can show if the vaccine triggers an immune response in participants that could fight off the virus. And while that means assessing societal needs and vaccination schedules for this particular novel coronavirus, Pfizer is also looking at the mRNA development platform it shares with BioNTech as "an important pillar", not only against COVID-19 but also existing and future viruses. Secondaries include prevention of severe COVID-19 in those groups.
The NCSC said it believes the attacks were done with the intent of stealing information and intellectual property related to COVID-19 vaccine research.
The individual was feeling fine, the agency reported.
That Times report mentions Pfizer's recent announcement it too has begun a late-stage COVID-19 vaccine study, working with BioNTech to enroll 30,000 people from 39 states in this country, Brazil, Argentina, and Germany.
The company, which is the world's largest vaccine manufacturer by number of doses produced and sold, globally, had last month signed an agreement with British-Swedish multinational pharmaceutical company AstraZeneca, the co-developer of the vaccine, to supply an additional 1 billion doses, principally for low- and middle-income countries.